JP2005508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508318A5
JP2005508318A5 JP2003528493A JP2003528493A JP2005508318A5 JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5 JP 2003528493 A JP2003528493 A JP 2003528493A JP 2003528493 A JP2003528493 A JP 2003528493A JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003528493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508318A (ja
JP4269052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/029232 external-priority patent/WO2003024395A2/en
Publication of JP2005508318A publication Critical patent/JP2005508318A/ja
Publication of JP2005508318A5 publication Critical patent/JP2005508318A5/ja
Application granted granted Critical
Publication of JP4269052B2 publication Critical patent/JP4269052B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003528493A 2001-09-14 2002-09-13 連結ビアリール化合物 Expired - Fee Related JP4269052B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32255601P 2001-09-14 2001-09-14
US33543401P 2001-11-30 2001-11-30
US37862702P 2002-05-07 2002-05-07
US38683302P 2002-06-06 2002-06-06
PCT/US2002/029232 WO2003024395A2 (en) 2001-09-14 2002-09-13 Linked biaryl compounds

Publications (3)

Publication Number Publication Date
JP2005508318A JP2005508318A (ja) 2005-03-31
JP2005508318A5 true JP2005508318A5 (enExample) 2006-01-05
JP4269052B2 JP4269052B2 (ja) 2009-05-27

Family

ID=27502245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528493A Expired - Fee Related JP4269052B2 (ja) 2001-09-14 2002-09-13 連結ビアリール化合物

Country Status (13)

Country Link
US (2) US6869975B2 (enExample)
EP (1) EP1435946B8 (enExample)
JP (1) JP4269052B2 (enExample)
KR (1) KR20040063897A (enExample)
CN (1) CN1585638A (enExample)
AU (1) AU2002336532C1 (enExample)
BR (1) BR0212512A (enExample)
CA (1) CA2460313C (enExample)
ES (1) ES2443642T3 (enExample)
IL (1) IL160845A0 (enExample)
MX (1) MXPA04002330A (enExample)
NZ (1) NZ531917A (enExample)
WO (1) WO2003024395A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
BR0212512A (pt) * 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004080283A2 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
WO2005012221A1 (ja) * 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1745014B1 (en) * 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP2007536341A (ja) * 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
US7544702B2 (en) * 2004-08-12 2009-06-09 Amgen Inc. Bisaryl-sulfonamides
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
WO2006060456A2 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as ppar ppar active compounds
US20060135540A1 (en) * 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005020229A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE102005020230A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
US7943669B2 (en) * 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
WO2007013694A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007030574A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
CN101304992A (zh) * 2005-09-07 2008-11-12 普莱希科公司 用作ppar调节剂的1,3-二取代吲哚衍生物
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
TW200730474A (en) 2005-12-29 2007-08-16 Schering Ag Diamine derivatives as inhibitors of leukotriene A4 hydrolease
CA2645719A1 (en) * 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
US9486441B2 (en) 2008-04-21 2016-11-08 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
KR20120115989A (ko) * 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
JP6562898B2 (ja) 2013-03-14 2019-08-21 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
CN113912547B (zh) * 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
BR112023001048A2 (pt) 2020-07-22 2023-04-04 Reneo Pharmaceuticals Inc Agonista de ppar-delta cristalino
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038934A (en) * 1959-03-17 1962-06-12 Smith Kline French Lab Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids
US4443536A (en) * 1981-08-25 1984-04-17 Eastman Kodak Company Nondiffusible photographic couplers and photographic elements and processes employing same
US4466902A (en) * 1982-01-31 1984-08-21 Ipposha Oil Industries, Co., Ltd. Rust inhibitor
EP0359169B1 (en) * 1988-09-14 1995-07-26 Eastman Kodak Company Photographic recording material comprising magenta coupler and a chalcogenazolium salt
EP0769052A2 (en) 1994-07-01 1997-04-23 The Salk Institute For Biological Studies Mammalian peroxisome proliferator-activated receptors and uses thereof
EP0882029B1 (en) 1996-02-02 2003-04-02 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
EP0904079B1 (en) 1996-02-02 2004-03-24 Merck & Co., Inc. Antidiabetic agents
WO1997028115A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Antidiabetic agents
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
AU726239B2 (en) * 1997-03-27 2000-11-02 Taisho Pharmaceutical Co., Ltd. 2-phenoxyaniline derivatives
US6300364B1 (en) 1997-07-24 2001-10-09 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
NZ505751A (en) 1997-12-23 2002-05-31 Commw Scient Ind Res Org Synthesis of tetrahydroxydiboron esters with acid sensitive alcohols in the presence of a Group VIII metal catalyst
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
KR100682276B1 (ko) * 1998-07-24 2007-02-28 데이진 가부시키가이샤 안트라닐산 유도체
JP2003500432A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP4295458B2 (ja) 1999-06-30 2009-07-15 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ活性調節用化合物
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
ES2215719T3 (es) 1999-09-08 2004-10-16 Glaxo Group Limited Antagonista ppar oxazol.
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
BRPI0112115B8 (pt) 2000-06-28 2021-05-25 Japan Tobacco Inc compostos moduladores ppar-gamma de quinolinil e benzotiazolil
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002070011A2 (en) 2001-02-02 2002-09-12 Smithkline Beecham Corporation Treatment of ppar mediated diseases
JP4499357B2 (ja) * 2001-02-14 2010-07-07 カロ・バイオ・アー・ベー 糖質コルチコイド受容体調節剤
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US7078422B2 (en) 2001-03-23 2006-07-18 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
IL159006A0 (en) * 2001-08-24 2004-05-12 Karobio Ab Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
BR0212512A (pt) 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
PT1431284E (pt) * 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
US7230031B2 (en) * 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Similar Documents

Publication Publication Date Title
JP2005508318A5 (enExample)
CA2460313A1 (en) Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
TWI339121B (en) 1-piperazine- and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic application thereof
CN102030700B (zh) 苯甲酰胺基羧酸类化合物及其制法和药物用途
US5606073A (en) Diazole-propenoic acid compounds
SG192439A1 (en) Organic compounds
CN109111426B (zh) 一类稠合双环杂芳基或芳基化合物，及其用途
TW200523250A (en) Compounds for inflammation and immune-related uses
JP2010526807A5 (enExample)
US20150368231A1 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
TW200815422A (en) Heteroaryl derivatives as cytokine inhibitors
JP2007500720A5 (enExample)
JP2009513703A5 (enExample)
JP2004529161A5 (enExample)
TW200901996A (en) Inhibitors of focal adhesion kinase
JP6579103B2 (ja) ハロゲン置換へテロ環化合物の塩
CN111285829A (zh) 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途
WO2010069124A1 (zh) 酰胺基噻唑衍生物及其制备方法和用途
CN103058949A (zh) 做为dhodh抑制剂的噻唑衍生物及其应用
CN101068784A (zh) 间烟碱化合物的羟基苯甲酸盐
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
JP2009506127A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
CN106117182B (zh) 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用
CN112739680A (zh) Dp拮抗剂
JP2011516445A (ja) Ｈｄｌ−コレステロール上昇剤としての３−トリフルオロメチル−ピラジン−２−カルボン酸アミド誘導体